{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:27:48Z","timestamp":1780662468068,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess efficacy of withdrawal or tapering biologic disease-modifying antirheumatic drugs (bDMARDs) vs. maintaining a standard regimen in patients with axial spondyloarthritis (axSpA) to sustain remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a systematic review of randomized controlled trials (RCTs) through July 2025, comparing treatment discontinuation or tapering against standard bDMARDs regimens in axSpA. We included RCTs of axSpA patients randomized to treatment interruption or tapering compared with standard treatment regimens. Outcomes measures included remission or flare measured by Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and acute phase reactants. We rated the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. We presented dichotomous outcomes as risk ratios (RR) with their 95% confidence intervals (CI). We used a random-effect model to perform a pooled analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight RCTs involving 1,384 participants were analyzed. For those in sustained remission &amp;gt;6 months, withdrawal led to a significantly lower rate of inactive disease state (RR 0.58, CI 0.45\u20130.76; high certainty) and increased risks of flare (RR 1.79, CI 1.34\u20132.38; high certainty) and partial flares (RR 1.57, CI 1.25\u20131.97; high certainty) compared to the standard regimen. Patients with short-term remission &amp;lt;6 months and treatment withdrawal experienced significantly higher rates of flares (RR 0.41 CI 0.23\u20130.72, low certainty) and increased disease activity (RR 0.36 CI 0.15\u20130.86, low certainty). Tapering in 211 patients showed non-significant risk reductions in maintaining remission or low disease activity (RR 0.89, CI 0.66\u20131.18; moderate certainty).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treatment withdrawal reduces the likelihood of maintaining inactive or low disease activity. Tapering does not significantly compromise the maintenance of remission or low disease activity offering a safer alternative to complete treatment withdrawal.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1621313","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:28:03Z","timestamp":1757482083000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of withdrawal or tapering of bDMARDs vs. standard regimen in axial spondyloarthritis patients: systematic review and meta-analysis informing the update of the Spanish Society of Rheumatology Guideline"],"prefix":"10.3389","volume":"12","author":[{"given":"Hye Sang","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00edaz del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Nieves","family":"Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Polo y La Borda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Guerra-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan D.","family":"Ca\u00f1ete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and treatment network recommendations for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2023-223937","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"105482","DOI":"10.1016\/j.jbspin.2022.105482","article-title":"Tapering or discontinuation of biological disease-modifying antirheumatic drugs in axial spondyloarthritis: a review of the literature and discussion on current practice","volume":"90","author":"Webers","year":"2023","journal-title":"Joint Bone Spine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1093\/rheumatology\/keab902","article-title":"Risk of flare after tapering or withdrawal of biologic\/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis","volume":"61","author":"Uhrenholt","year":"2022","journal-title":"Rheumatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.reumae.2024.07.010","article-title":"Management, development and methodology of the clinical practice guidelines and recommendations of the Spanish society of rheumatology","volume":"20","author":"D\u00edaz del Campo Fontecha","year":"2024","journal-title":"Reumatol Cl"},{"key":"B7","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jclinepi.2020.09.018","article-title":"GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence-an overview in the context of health decision-making","volume":"129","author":"Brozek","year":"2021","journal-title":"J Clin Epidemiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTT.S31474","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1093\/rheumatology\/kead112","article-title":"Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)","volume":"62","author":"Weinstein","year":"2023","journal-title":"Rheumatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","article-title":"Dosing down with biologic therapies: a systematic review and clinicians' perspective","volume":"56","author":"Edwards","year":"2017","journal-title":"Rheumatology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keab330","article-title":"Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study","volume":"61","author":"Hazlewood","year":"2022","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12969-024-01046-3","article-title":"Approaches and outcomes of adalimumab discontinuation in patients with well-controlled inflammatory arthritis: a systematic search and review","volume":"22","author":"Balay-Dustrude","year":"2024","journal-title":"Pediatr Rheumatol Online J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/acr.24184","article-title":"Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Lawson","year":"2021","journal-title":"Arthritis Care Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"112167","DOI":"10.1016\/j.intimp.2024.112167","article-title":"Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: a meta-analysis and literature review","volume":"134","author":"Min","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"105468","DOI":"10.1016\/j.jbspin.2022.105468","article-title":"Challenges in non-radiographic axial spondyloarthritis","volume":"90","author":"Poddubnyy","year":"2023","journal-title":"Joint Bone Spine."},{"key":"B24","article-title":"Defining BASDAI cut-offs for disease activity states in axial spondylarthritis \u2013 results from the EuroSpA Collaboration [abstract]","author":"Georgiadis","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1621313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:28:05Z","timestamp":1757482085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1621313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1621313"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1621313","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"1621313"}}